Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

Acute Kidney Injury Clinical Trial

Official title:

Impact of Neohepatic Albumin-Bilirubin Scores on Renal Outcomes Following Living-donor Liver Transplantation: Propensity Score Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06340607
• Other study ID #: 2023-0561
• Status: Completed
• Start date: January 5, 2012
• Est. completion date: December 31, 2022

Study information

• Verified date: March 2024
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Description:

Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3422
• Est. completion date: December 31, 2022
• Est. primary completion date: January 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• living donor liver transplantation recipients (=18 years)

Exclusion Criteria:

• preoperative serum creatinine (sCr) > 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

Related Conditions & MeSH terms

• Acute Kidney Injury
• Chronic Kidney Diseases
• Graft Failure
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul	Song-pa Gu

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	acute kidney injury	determined by change in sCr according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition (increase in sCr of =26.5 mmol litre-1 within 48h or =1.5 times baseline within 7 days after surgery	within 7 days after surgery
Secondary	chronic kidney injury	when renal function assessed by calculating estimated serum glomerular filtration using the abbreviated modification of diet in renal disease equation was <60 mL/min/1.73 m2 for 3 months or more, irrespective of cause	within 1 year after surgery
Secondary	graft failure	graft failure	the graft failure at overall period (calculated from the date of surgery to the last follow-up) from the date of surgery (up to 10 years)]